Literature DB >> 12797452

Cross-presentation of cell-associated antigens by dendritic cells.

M Larsson1, J F Fonteneau, N Bhardwaj.   

Abstract

There is a strict requirement for professional antigen-presenting cells (APCs) in the generation of immunity toward most viruses. Exogenous pathways of MHC class I-restricted antigen presentation play an important role in the generation of antiviral immunity, particularly in the immune surveillance of virus-infected tissues of nonhematopoietic origin, and to bypass the detrimental effects of direct virus infection on professional APCs. The mechanisms underlying generation of antiviral immunity under these circumstances are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797452     DOI: 10.1007/978-3-662-06508-2_12

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  13 in total

1.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio.

Authors:  Rahnuma Wahid; Martin J Cannon; Marie Chow
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 3.  Dendritic cell based vaccines for HIV infection: the way ahead.

Authors:  Felipe García; Montserrat Plana; Nuria Climent; Agathe León; Jose M Gatell; Teresa Gallart
Journal:  Hum Vaccin Immunother       Date:  2013-08-02       Impact factor: 3.452

4.  Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Authors:  Xuemin Chen; Michael T Rock; Jason Hammonds; James Tartaglia; Ayumi Shintani; Jeff Currier; Bonnie Slike; James E Crowe; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection.

Authors:  José Peña; Mario Frías; Laura Castro-Orgaz; Rafael González; Felipe García; Teresa Gallart; Jose María Gatell; Montserrat Plana
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

6.  Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression.

Authors:  Marta Rodríguez-García; Núria Climent; Harold Oliva; Víctor Casanova; Rafael Franco; Agathe Leon; José M Gatell; Felipe García; Teresa Gallart
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 7.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

8.  Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.

Authors:  O Manches; G Lui; J P Molens; J J Sotto; L Chaperot; J Plumas
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

9.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.